The recent trial results from Danish pharmaceutical company Novo Nordisk have sent shockwaves through the weight loss drug market. The company aimed to showcase its new treatment as superior to competing products from Eli Lilly, specifically Mounjaro and Zepbound. However, the findings revealed that Eli Lilly’s drugs outperformed Novo’s, causing substantial repercussions for the company’s stock and raising concerns about the competitive landscape in the obesity treatment sector.
In a head-to-head trial conducted over 84 weeks with more than 800 participants, Novo’s new treatment failed to meet expectations, as reported last month. Analysts noted that the results represented a significant setback, with one stating that Novo had “shot itself in the foot.” Following the announcement, headlines from major business outlets like Bloomberg and CNBC indicated that Eli Lilly’s Mounjaro had extended its lead in the U.S. market. Consequently, billions were wiped off Novo’s market value, while Eli Lilly’s stock remained robust, keeping its market valuation near $1 trillion.
The implications of this trial extend beyond the pharmaceutical sector, as Ireland has a considerable economic interest in the ongoing competition between these two giants. While the country is home to tech titans such as Apple and Microsoft, it also relies heavily on the jobs and corporation taxes generated by global pharmaceutical firms like Novo and Eli Lilly.
The pharmaceutical industry plays a vital role in Ireland’s economy, with many towns hosting manufacturing plants that produce some of the world’s best-selling medicines. For instance, AbbVie employs 2,900 people in the Republic, while Pfizer employs around 5,000 across various locations. The latest research from the Economic and Social Research Institute indicates that over 23,000 individuals are employed by nine major pharmaceutical companies operating in Ireland.
The value of medical and pharmaceutical exports reached €138 billion last year, accounting for a substantial portion of the total €260 billion in goods exported from Ireland. This figure dwarfs exports from other significant sectors, such as meat and dairy, which totaled €16 billion. While the exact contribution of weight loss drugs produced in Ireland remains unknown, Eli Lilly’s recent investments provide some insights into the sector’s growth potential.
In 2024, Eli Lilly committed nearly $10 billion to production facilities in Indiana for drugs, including Tirzepatide, the active ingredient in Mounjaro and Zepbound. The company also invested $1.8 billion in its Irish operations, a figure that has since grown to $4.3 billion. This expansion underscores Ireland’s role in meeting global demand for obesity and diabetes medications.
Eli Lilly’s recent financial documents indicate significant tax contributions, with cash payments of corporation taxes amounting to $6.6 billion in Ireland, compared to $3.3 billion in the United States. This increase is attributed to heightened production activities aimed at satisfying rising global demand for their medicines.
Interestingly, estimates from the Irish Fiscal Advisory Council suggest that Eli Lilly has surpassed Pfizer as a major contributor to the Irish government’s revenue. The company stands alongside Apple and Microsoft as one of the top three contributors to last year’s €35 billion corporation tax collection.
While the Irish government typically keeps the identities of its largest corporate taxpayers confidential, public filings from companies like Eli Lilly offer valuable information about their contributions to the economy. Eli Lilly, which employs 3,700 people across three locations in Ireland, continues to expand its manufacturing capabilities, including a recent project in Limerick.
Meanwhile, Novo Nordisk announced plans to invest €432 million in expanding its facility in Monksland, Athlone, to produce Wegovy in pill form for international markets. Despite its recent setbacks, Novo remains a key player in the global pharmaceutical landscape, employing around 69,000 individuals worldwide.
As both Eli Lilly and Novo compete for dominance in the growing obesity drug market, the Irish government appears to be strategically positioned, hoping that this rivalry will yield continued economic benefits for the nation. The outcome of this competition will undoubtedly influence the future of the pharmaceutical industry in Ireland and beyond.
